Physician profile
Cameron Duncan
NPI 1629372800
$2,689.30
in general payments reported to CMS, 2019-2025
22 companies · $55.42 in 2025
The $55.42 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,200 · 2022: $638 · 2023: $525 · 2024: $271 · 2025: $55.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.77 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.70 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.96 | 2021-2022 | |
| Indivior INC. | $149.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $147.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $140.24 | 2021-2023 | Spravato |
| Lucid Diagnostics INC. | $113.32 | 2023 | |
| Sunovion Pharmaceuticals INC. | $105.67 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $72.56 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $70.36 | 2021-2022 | |
| Eisai INC. | $64.52 | 2021-2022 | |
| Amgen INC. | $49.70 | 2021 | |
| Corium, LLC | $45.39 | 2023-2024 | Azstarys |
| Alkermes, INC. | $33.98 | 2021-2022 | |
| Pfizer INC. | $25.34 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $22.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.20 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2022 | |
| Lundbeck LLC | $12.93 | 2021 | |
| Lilly USA, LLC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.